Patent ID: 8440695

Claim:
A method for increasing Ataxia-Telangiectasia Mutated (ATM) protein kinase activity in a mammal with metabolic syndrome, which method comprises administering an effective amount of a chloroquine compound to a mammal in need of such treatment, wherein the chloroquine compound (i) enhances the activity of ATM kinase in the mammal and (ii) is selected from the group consisting of mefloquine, pyronaridine, piperaquine, amodiaquine, and quinidine, enantiomers thereof, pharmaceutically acceptable salts thereof, and mixtures thereof, or has a structure of Formula I: wherein R 1 to R 6 are independently selected from hydrogen or alkyl, provided that no more than two substituents from R 1 to R 6 may be simultaneously alkyl; R 7 and R 8 is hydrogen, alkyl, alkenyl or aralkyl, or together with the N atom signify pyrrolidine or piperidine, which optionally can be substituted by alkyl, or octahydroindole or 3-azabicyclo[3,2,2]nonane; R 9 is hydrogen or halogen; R 10 is halogen or trifluoromethyl; and n =0 or 1; or wherein the symbols R 1 and R 3 is tri- or tetramethylene; R 2 and R 4 to R 6 is hydrogen; n =0; and R 7 and R 8 are defined as above; or wherein the symbols R 1 and R 7 is methylene or dimethylene and n=1, or R 1 and R 7 are di- or trimethylene and n =0, or R 3 and R 7 are di- or trimethylene and n =1, or R 3 and R 7 are tri- or tetramethylene and n =0, or R 5 and R 7 are tri- or tetramethylene and n =1, or R 1 and R 5 are di- or tri-methylene and n =1, and the remaining substituents are hydrogen, except R 8 which is alkyl, alkenyl or alkynyl; wherein the symbols R 3 and R 5 is tri- or tetramethylene and n =1; all remaining substituents to R 6 are hydrogen; and R 7 and R 8 are alkyl, alkenyl or aralkyl or together with the N atom are pyrrolidine or piperidine, which optionally can be substituted by alkyl; R 9 is hydrogen or halogen; and R 10 is halogen or trifluoromethyl, enantiomers thereof, pharmaceutically acceptable salts thereof, and mixtures thereof.